GLP-1, or {glucagon-like|glucagon like|glucagon) peptide-1, is rapidly emerging as a significant focus in healthcare studies, largely due to its notable impact on treating conditions such as type 2 diabetes and obesity. Ongoing research have shown that in addition to glucose control, GLP-1 agonists offer potential for cardiovascular well-being and